Deepening its integration with digitalization, the pharmaceutical company established a digital technology company

【Pharmaceutical Network Enterprise News】Recently, it is reported that Wuhan Medical Bank Digital Technology Co.
, Ltd.
, which is controlled by Hengrui Pharmaceutical, was established, the legal representative is Sun He, the registered capital is 10 million yuan, and the business scope includes: pharmaceutical Internet information services; Internet information services; Internet information services for medical devices; The second type of value-added telecommunications services, etc
.
Hengrui Pharmaceutical is an international pharmaceutical enterprise engaged in the development and promotion of innovative and high-quality drugs, in recent years, Hengrui Pharmaceutical has been continuously improving the level
of production automation, intelligence and digitalization while increasing the innovation ability and international development of new drugs.
In 2017, it was approved as a provincial demonstration intelligent workshop project, and in 2018, Hengrui Innovative Pharmaceutical Preparation Project Phase III Intelligent Factory was successfully approved as a smart factory demonstration project
in Jiangsu Province.
At present, Hengrui Pharmaceutical has more than ten subsidiaries, with more and more abundant product lines, a large number of suppliers, increasing management complexity, higher and higher requirements for digital supply chains, and continuous deepening
of integration with digitalization.
It is reported that in order to improve the overall operation efficiency of the supply chain and meet the new procurement needs of the group and subsidiaries brought about by the rapid development of the company, Hengrui Pharmaceutical also signed a contract with Zhenyun Technology in 2021, and the two parties reached a consensus on the implementation plan of the procurement management platform to jointly provide more agile solutions
for the digital transformation of Hengrui Pharmaceutical's supply chain.
In fact, with the development of cloud computing, 5G, Internet, big data and other technologies, a large number of pharmaceutical companies are currently building core competitiveness
through digitalization, big data, and AI.
In addition to the establishment of digital companies, the cooperation between pharmaceutical companies and digital enterprises and platforms has been increasing
in recent years.
On October 27, XtalPi announced a research collaboration with Janssen Pharmaceuticals ("Janssen"), a subsidiary of Johnson & Johnson, to provide Janssen with new structural compound design, screening, and synthesis services
.
Under the agreement, XtalPi will provide Janssen's specific targets with small molecule active molecules
with characteristic specifications.
XtalPi will deploy its comprehensive end-to-end platform, inclusive digital drug discovery and development, which includes proprietary cloud-based computing and advanced wet lab capabilities designed to shorten the design-make-test-analyze (DMTA) cycle
.
On October 24, Salubris also signed a cooperation agreement
with Alpha Molecule to jointly develop new drugs.
According to the agreement, the cooperation between Salubris and Alpha Molecule will combine Salubris' drug discovery, development and clinical translation capabilities with Alpha Molecule's biocomputing, AI and original biotechnology to further improve the efficiency and success rate of new drug research and development, and achieve a win-win situation
for both parties in the field of new drug research and development.
In addition, China Resources Sanjiu also mentioned in research activities that the company has built a digital center, transformed traditional businesses and built new businesses, and has achieved certain results
.
At the same time, the company also lays out intelligent manufacturing in its digital strategy, connecting the consumer end and the manufacturing end and the front-end traceability of traditional Chinese medicine
.
It said that it hopes to build a mature digital business model
through 2-3 years of hard work.
.
.
.
.
.
.
In general, among the various industrial roles in the medical and health industry, the pharmaceutical industry, as a provider of diagnosis and treatment solutions, is moving from the initial stage to a deeper direction, and in the future, with the continuous integration of pharmaceutical enterprises and digitalization, digital technologies and platforms will help all major players in the medical and health industry to achieve comprehensive digital transformation
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.